Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Citius Oncology, Inc.NASDAQ: CTOR
Research & Development · Q2 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q2 FY2026 research & development of $1.08M fell 65.6% year over year, behind the -39.8% change in trailing-twelve-month research & development. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at -2.2% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -65.6% toward the trailing-twelve-month pace of -39.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.42M USD
- Year-over-year change
- +30.3%
- 3-year CAGR
- -2.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 6.42M | +30.3% |
| FY2024 | 2024-09-30 | 4.93M | +16.1% |
| FY2023 | 2023-09-30 | 4.24M | -38.1% |
| FY2022 | 2022-09-30 | 6.86M | — |
Research & Development vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 research & development of $4.11M is the lowest of the 10 companies compared; the peer median is $27.77M.
- Its year-over-year change of -39.8% is the 9th highest of 10, against a peer median of +1.0%.
- Research & development amounts to 73.3% of revenue for CTOR, versus a peer median of 57.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $312.43M | +226.5% | +70.8% | — | |
| LTM Mar 2026 | $100.48M | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $65.43M | +123.8% | +118.4% | — | |
| LTM Mar 2026 | $37.82M | -33.6% | -23.5% | 3297.1% | |
| LTM Mar 2026 | $27.77M | -70.1% | -6.9% | 50.7% | |
| LTM Mar 2026 | $21.46M | +138.8% | +31.8% | 63.4% | |
| LTM Mar 2026 | $15.13M | +46.7% | -20.4% | 14.1% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $9.64M | -35.9% | -14.4% | — |
| LTM Mar 2026 | $5.47M | +1.0% | -21.9% | 9.5% | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $4.11M | -39.8% | -2.2% | 73.3% |
| Peer median (excluding CTOR) | $27.77M | +1.0% | -14.4% | 57.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 6.86M | 4.24M | 4.93M | 6.42M |
| Selling, General & Admin | 2.86M | 7.88M | 15.65M | 17.1M |
| Operating Expenses | 9.71M | 12.12M | 20.57M | 23.52M |
| Depreciation & Amortization | 9.71M | 0 | 0 | 0 |
| EBITDA | 0 | (12.12M) | (20.57M) | (23.49M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (9.71M) | (12.12M) | (20.57M) | (23.52M) |
| Operating Margin | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 36.37K |
| Interest Expense | 0 | 0 | 0 | 218.03K |
| Other Income / Expenses | 0 | 0 | 0 | (181.66K) |
| Income Before Tax | (9.71M) | (12.12M) | (20.57M) | (23.7M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1.15M | 576K | 576K | 1.06M |
| Net Income | (10.87M) | (12.7M) | (21.15M) | (24.76M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.08) | (0.19) | (0.30) | (0.34) |
| EPS (Diluted) | (0.08) | (0.19) | (0.30) | (0.34) |
| Weighted Avg Shares | 90.16M | 89.48M | 71.55M | 73.27M |
| Weighted Avg Shares (Diluted) | 90.16M | 89.48M | 71.55M | 73.27M |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.